AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Passage BIO, Inc. Director's Dealing 2020

Mar 2, 2020

34849_dirs_2020-03-02_7918b806-6c89-4c8a-a6c0-2470cb9c7639.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2020-02-27

Reporting Person: Quigley Jill M. (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-27	Employee Stock Option (Right to Buy)	$18.00	A	211001	Acquired	2030-02-27	Common Stock (211001)	Direct

Footnotes

F1: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.